Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement

[1]  S. Eubank,et al.  Commentary on Ferguson, et al., “Impact of Non-pharmaceutical Interventions (NPIs) to Reduce COVID-19 Mortality and Healthcare Demand” , 2020, Bulletin of Mathematical Biology.

[2]  C. Eastin,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The Journal of Emergency Medicine.

[3]  T. Lancet,et al.  COVID-19: protecting health-care workers , 2020, The Lancet.

[4]  Ezekiel J Emanuel,et al.  Fair Allocation of Scarce Medical Resources in the Time of Covid-19. , 2020, The New England journal of medicine.

[5]  U. Ricardi,et al.  Running a Radiation Oncology Department at the Time of Coronavirus: An Italian Experience , 2020, Advances in Radiation Oncology.

[6]  F. Puglisi,et al.  Managing COVID-19 in the oncology clinic and avoiding the distraction effect , 2020, Annals of Oncology.

[7]  R. Corvò,et al.  Letter from Italy: First practical indications for radiation therapy departments during COVID-19 outbreak , 2020, International Journal of Radiation Oncology*Biology*Physics.

[8]  Lisa Rosenbaum,et al.  Facing Covid-19 in Italy - Ethics, Logistics, and Therapeutics on the Epidemic's Front Line. , 2020, The New England journal of medicine.

[9]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[10]  Jessica T Davis,et al.  The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak , 2020, Science.

[11]  Huahao Shen,et al.  Risk of COVID-19 for patients with cancer , 2020, The Lancet Oncology.

[12]  H. Bai,et al.  [Individualized treatment recommendations for lung cancer patients at different stages of treatment during the outbreak of 2019 novel coronavirus disease epidemic]. , 2020, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[13]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[14]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[15]  M. Christian.  Triage , 2019, Critical Care Clinics.

[16]  Joe Y. Chang,et al.  Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer. , 2017, International journal of radiation oncology, biology, physics.

[17]  P. Iyengar,et al.  A Phase III Randomized Study of Image Guided Conventional (60 Gy/30 fx) Versus Accelerated, Hypofractionated (60 Gy/15 fx) Radiation for Poor Performance Status Stage II and III NSCLC Patients—An Interim Analysis , 2016 .

[18]  Xian-Jin Xie,et al.  Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial. , 2015, International journal of radiation oncology, biology, physics.

[19]  N. O'Rourke,et al.  SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status. , 2014, European journal of cancer.

[20]  Forum on Medical.  FORUM ON MEDICAL AND PUBLIC HEALTH PREPAREDNESS FOR CATASTROPHIC EVENTS , 2013 .

[21]  V. De Sanctis,et al.  Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer. , 2013, International journal of radiation oncology, biology, physics.

[22]  M. Scherer,et al.  Methods for the guideline-based development of quality indicators--a systematic review , 2012, Implementation Science.

[23]  Chia-Chien Hsu,et al.  The Delphi Technique: Making Sense of Consensus , 2007 .

[24]  G. Giaccone,et al.  Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). , 2007, European journal of cancer.

[25]  A. Bezjak,et al.  Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). , 2002, International journal of radiation oncology, biology, physics.

[26]  D. Girling,et al.  Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party. , 1996, Clinical oncology (Royal College of Radiologists (Great Britain)).

[27]  D. Machin,et al.  A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party. , 1992, British Journal of Cancer.